5d
GlobalData on MSNAstraZeneca’s Imfinzi bladder cancer regimen improves survival in Phase III trialThe treatment regimen reduced the risk of developing distant metastases or death due to bladder cancer by 33%.
The phase 3 NIAGARA trial randomised 1,063 MIBC patients to receive Imfinzi plus neoadjuvant chemotherapy prior to bladder ...
2d
Zacks.com on MSNAstraZeneca Rises Almost 9% in a Month: How to Play the StockAstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...
5don MSN
Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors ...
Bristol Myers Squibb has bolstered its case for Opdivo to be used as a pre-operative treatment for non-small cell lung cancer ...
Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...
AstraZeneca 4Q Revenues: $14.9 billion (+24%) 4Q Earnings: $1.5 billion (+56%) FY Revenues: $54.1 billion (+18%) FY Earnings: $7.0 billion (+18%) Comments: Oncology sales were $22.4 billion, up 21%.
AstraZeneca PLC outperforms 2024 earnings estimates but faces challenges in 2025. Read why AZN patent expiries and mixed ...
FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its ...
We recently published a list of 12 Best Global Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best ...
3d
News Medical on MSNRadiation, Immunotherapy May Preserve Bladder in CancerPatients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results